E-drug: Re: New leadership in WHO
----------------------------------------------------------
In follow-up to the message about the new executive directors, here is
a description of Scholtz.
The new executive director for Health technology and Drugs is Dr Michael
Scholtz. A personal description can be found at:
http://www.who.ch/inf-dg/biographies/michael_scholtz.html
The text:
The Director-General of the World Health Organization, Dr Gro Harlem
Brundtland, appointed Dr Michael Scholtz Executive Director � Health
Technology and Drugs, effective 21 July 1998. In this post, Dr Scholtz
will be responsible for essential drugs; informatics; drug management
and policy; vaccines and immunization and health technology. Dr Scholtz
has spent his professional career in the pharmaceutical industry with a
variety of marketing and management responsibilities. His experience in
the private sector will add to the knowledge base of WHO and help it
deal effectively with the complex field of health technology, drug
development and how to make new drugs available and affordable.
Dr Scholtz was born in 1950 in Hamburg (Germany). He received a Ph.D. Dr
rer. Nat. in Organic Chemistry from the Carolo-Wilhelmina University in
Braunschweig (Germany).
Dr Scholtz joins WHO from SmithKline Beecham Biologicals, where he was
Vice-President & Director Marketing Operation. In this role he was
responsible for Strategic Planning, sales in public and private market
segments including supra-national agencies, medical information,
business communication and supervised the formation of alliances with
foreign companies and public vaccine manufacturers.
Dr Scholtz began his career in 1976 in Ciba-Geigy (Germany) where he
held several positions in sales, marketing and medical information with
a focus on cardiovascular products. In 1986 he was appointed
International Products Manager and later named Group Head,
Cardiovascular Products, in Central Product Management of Ciba-Geigy,
Basel (Switzerland). In 1991 Dr Scholtz relocated to Philadelphia (USA)
to join SmithKline Beecham Pharmaceuticals as Vice-President & Director
in Worldwide Strategy Product Development, with responsibility for
cardiovascular and later also pulmonary products.
Dr Scholtz is married with two children.
Mark Raijmakers, Wemos
wemos@wemos.nl
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.